Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + Chemotherapy in First-Line Recurrent/Metastatic SCCHN
NCT00122460Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Dec 2004
- Primary completion
- Mar 2007
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial of KL-140 in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by Merck KGaA. Primary endpoint: Overall Survival Time up to 27 months. Started Dec 2004; status: completed.
02
Drugs
KL-140
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00122460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00122460.